tbuckley/cabot-search huggingface dataset:
THE RIGHT HONORABLE SIR THOMAS CLIFFORD ALLBUTT
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
Authors: Josefin Eklöf, Maria A. Misiakou, Pradeesh Sivapalan, Karin Armbruster, Andrea Browatzki, Thyge L. Nielsen, Therese S. Lapperre, Helle F. Andreassen, Julie Janner, Charlotte S. Ulrik, Migle Gabrielaite, Helle K. Johansen, Annemette Jensen, Tine V. Nielsen, Frederik B. Hertz, Khaled Ghathian, Henrik Calum, Torgny Wilcke, Niels Seersholm, Jens-Ulrik S. Jensen, Rasmus L. Marvig
Journal: Clinical Microbiology and Infection (2022)

It is unclear whether recurrent sputum culture with Pseudomonas aeruginosa from patients with chronic obstructive pulmonary disease (COPD) is caused by intermittent airway carriage by different P. aeruginosa lineages or persistent carriage by the same lineage, and whether lineages genetically adapt during carriage.Whole-genome sequencing was performed for P. aeruginosa isolates sampled longitudinally from sputum cultures in patients with COPD who were enrolled in an ongoing randomized controlled trial (clinicaltrials.gov: NCT03262142).A total of 153 P. aeruginosa isolates were sequenced for 23 patients during 365 days of follow-up. Recurrent presence of P. aeruginosa was seen in 19 patients (83%) and was caused by persistence of the same clonal lineage in all but one patient. We identified 38 genes mutated in parallel in two or more lineages, suggesting positive selection for adaptive mutations. Mutational enrichment analysis revealed genes important in antibiotic resistance and chronic infections to be more frequently mutated.Recurrent P. aeruginosa was common and carried for a prolonged time after initial detection in the airways of patients with COPD. Recurrence was caused by persistence of the same clonal lineage and was associated with genetic adaptation. Trial data on possible clinical benefits of attempting antibiotic eradication of P. aeruginosa in COPD are warranted.
Abstract 264: Traumatic and Hemorrhagic Complications After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
Authors: My-Linh Nguyen, Emma Gause, Brianna Mills, Joseph Tonna, Heidi Alvey, Richard Saczkowski, Brian E Grunau, Lance B Becker, David F Gaieski, Scott T Youngquist, Jessica Hamilton, Jenelle Badulak, Samuel Mandell, Eileen Bulger, Nicholas J Johnson
Journal: Circulation (2020)

Introduction: Extracorporeal cardiopulmonary resuscitation (ECPR) is a rescue therapy for treatment of refractory out-of-hospital cardiac arrests (OHCA). We describe the incidence of traumatic and hemorrhagic complications among patients undergoing ECPR for OHCA and the association between CPR duration and ECPR-related injuries or bleeding. Methods: We examined prospectively collected data from the Extracorporeal Resuscitation Outcomes Database (EROD), which includes ECPR-treated OHCAs from participating hospitals (Oct 2014 - Aug 2019). The primary outcome was traumatic or hemorrhagic complications, defined as injury to the chest, abdomen, or vasculature, or bleeding requiring transfusion or surgery. The primary exposure was the cardiac arrest to ECPR initiation interval (CA-ECPR interval), measured as the time from arrest to initiation of ECPR. Descriptive statistics were used to compare demographic, cardiac arrest, and ECPR characteristics among patients with and without CPR-related traumatic or bleeding complications. Multivariable logistic regression was used to examine the association between CPR duration and traumatic or bleeding complications. Results: A total of 68 patients from 4 hospitals received ECPR for OHCA were entered into EROD and met inclusion criteria. Median age was 51 (IQR 38-58), 81% were male, 40% had BMI &gt; 30, and 70% had pre-existing medical comorbidities. A total of 65% had an initial shockable cardiac rhythm, mechanical CPR was utilized in at least 29% of patients, and 27% were discharged alive. A total of 37% experienced a traumatic or bleeding complication, with major bleeding (32%), vascular injury (18%), and cannula site bleeding (15%) being the most common. Compared to patients with shorter CPR times, patients with a 10 minute longer CA-ECPR interval had 18% (95% CI -2-42%) higher odds of suffering a mechanical or bleeding complication, but this did not reach statistical significance (p=0.08). Conclusions: Traumatic injuries and bleeding complications are common among patients undergoing ECPR. Further study is needed to investigate the relation between arrest duration and complications. Clinicians performing ECPR should anticipate and assess for injuries and bleeding in this high-risk population.
Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial
Authors: Steve Turner, Seonaidh Cotton, Jessica Wood, Victoria Bell, Edwin-Amalraj Raja, Neil W Scott, Heather Morgan, Louisa Lawrie, David Emele, Charlotte Kennedy, Graham Scotland, Shona Fielding, Graeme MacLennan, John Norrie, Mark Forrest, Erol A Gaillard, Johan de Jongste, Marielle Pijnenburg, Mike Thomas, David Price
Journal: The Lancet Respiratory Medicine (2022)
Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant
Authors: Branavan Manoranjan, Abdelsimar T Omar, Hai-Bo Wu, Robert Nordal, Yves P Starreveld
Journal: Neuro-Oncology (2022)

SMARCB1 (SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily B, member 1), also known as INI1, is a tumor suppressor gene that encodes a core subunit of the SWI/SNF chromatin-remodeling complex, which functions as an essential epigenetic regulator during development.1 Biallelic inactivation of SMARCB1 has been associated with the growth of benign and malignant tumors in children and adults.1 Intracranial SMARCB1-deficient tumors primarily arise in children and include malignant atypical teratoid/rhabdoid tumor (ATRT), benign cribriform neuroepithelial tumor, and poorly differentiated chordoma.1 The recent description of adult intracranial SMARCB1-deficient tumors with unique histology and indeterminate prognostic data2–4 would suggest these tumors to be part of a developmental spectrum of which ATRT is the most malignant. Herein, we describe the clinical management of one such adult intracranial SMARCB1-deficient tumor that has yet to be described by the World Health Organization Classification of Central Nervous System Tumors, desmoplastic myxoid tumor (DMT), SMARCB1-mutant. Available demographic data (Table 1) from all prior cases indicate no gender differences (F: 6; M: 4) and an average age of onset of 36.6 years (range 15-61 years old). Of note, all prior cases have been in the pineal region. The surgical management of DMT, SMARCB1-mutant cases has included subtotal resection (4/10) or gross total resection (6/10). Only 2 cases were initially treated with an endoscopic third ventriculostomy due to obstructive hydrocephalus. Adjuvant chemotherapy (1/10) or radiotherapy (4/10) have been provided in a minority of cases. Reports to date have not defined the coordinated use of radiotherapy with surgery. Our previously reported case5 has been the only case with cerebrospinal fluid (CSF) dissemination, which presented a therapeutic challenge. We chose to treat this patient with a subtotal resection followed by curative intent craniospinal irradiation with a radiation boost to the primary tumor region. In total, 36 Gy was delivered to the neuraxis in 20 fractions and an additional 19.8 Gy was given to the primary tumor volume in 11 fractions. Our patient remains clinically well with a significant reduction in tumor size with no signs of intracranial CSF dissemination or spinal drop metastases on MRI following surgical resection and radiotherapy. We were able to obtain more recent follow-up data on one additional previously reported case,4 who remains disease-free at 12-month post-GTR and radiotherapy. With a median follow-up of 29.5 months (0 months-7 years), 30% (3/10) of tumors have resulted in death, while the remainder are alive with stable disease or no signs of recurrence.
Maternal Glycemic Dysregulation During Pregnancy and Neonatal Blood DNA Methylation: Meta-analyses of Epigenome-Wide Association Studies
Authors: Elmar W. Tobi, Diana L. Juvinao-Quintero, Justiina Ronkainen, Raffael Ott, Rossella Alfano, Mickaël Canouil, Madelon L. Geurtsen, Amna Khamis, Leanne K. Küpers, Ives Y. Lim, Patrice Perron, Giancarlo Pesce, Johanna Tuhkanen, Anne P. Starling, Toby Andrew, Elisabeth Binder, Robert Caiazzo, Jerry K.Y. Chan, Romy Gaillard, Peter D. Gluckman, Elina Keikkala, Neerja Karnani, Sanna Mustaniemi, Tim S. Nawrot, François Pattou, Michelle Plusquin, Violeta Raverdy, Kok Hian Tan, Evangelia Tzala, Katri Raikkonen, Christiane Winkler, Anette-G. Ziegler, Isabella Annesi-Maesano, Luigi Bouchard, Yap Seng Chong, Dana Dabelea, Janine F. Felix, Barbara Heude, Vincent W.V. Jaddoe, Jari Lahti, Brigitte Reimann, Marja Vääräsmäki, Amélie Bonnefond, Philippe Froguel, Sandra Hummel, Eero Kajantie, Marjo-Riita Jarvelin, Regine P.M. Steegers-Theunissen, Caitlin G. Howe, Marie-France Hivert, Sylvain Sebert
Journal: Diabetes Care (2022)

Maternal glycemic dysregulation during pregnancy increases the risk of adverse health outcomes in her offspring, a risk thought to be linearly related to maternal hyperglycemia. It is hypothesized that changes in offspring DNA methylation (DNAm) underline these associations.
Rapid 3D bioprinting of a multicellular model recapitulating pterygium microenvironment
Authors: Zheng Zhong, Jing Wang, Jing Tian, Xiaoqian Deng, Alis Balayan, Yazhi Sun, Yi Xiang, Jiaao Guan, Jacob Schimelman, Henry Hwang, Shangting You, Xiaokang Wu, Chao Ma, Xiaoao Shi, Emmie Yao, Sophie X. Deng, Shaochen Chen
Journal: Biomaterials (2022)

Pterygium is an ocular surface disorder with high prevalence that can lead to vision impairment. As a pathological outgrowth of conjunctiva, pterygium involves neovascularization and chronic inflammation. Here, we developed a 3D multicellular in vitro pterygium model using a digital light processing (DLP)-based 3D bioprinting platform with human conjunctival stem cells (hCjSCs). A novel feeder-free culture system was adopted and efficiently expanded the primary hCjSCs with homogeneity, stemness and differentiation potency. The DLP-based 3D bioprinting method was able to fabricate hydrogel scaffolds that support the viability and biological integrity of the encapsulated hCjSCs. The bioprinted 3D pterygium model consisted of hCjSCs, immune cells, and vascular cells to recapitulate the disease microenvironment. Transcriptomic analysis using RNA sequencing (RNA-seq) identified a distinct profile correlated to inflammation response, angiogenesis, and epithelial mesenchymal transition in the bioprinted 3D pterygium model. In addition, the pterygium signatures and disease relevance of the bioprinted model were validated with the public RNA-seq data from patient-derived pterygium tissues. By integrating the stem cell technology with 3D bioprinting, this is the first reported 3D in vitro disease model for pterygium that can be utilized for future studies towards personalized medicine and drug screening.
The Association between Public versus Private Insurance and Poor Asthma Control in the Pediatric Population Using the 2013 and 2018 National Health Interview Survey
Authors: David Sanchez, Gregory L. Peck, Farhana Haque, Benjamin Allar, Margee Louisias, Gezzer Ortega, Michelle Bover Manderski
Journal: Journal of Allergy and Clinical Immunology (2022)
NCCN Guidelines® Updates: Gastric Cancer
Journal: Journal of the National Comprehensive Cancer Network (2022)

Workup:➤ 9th bullet was revised: "Universal testing for MSI by PCR/MMR PCR/ next-generation sequencing (NGS) or MMR by IHC is recommended in all newly diagnosed patients."➤ 11th bullet was revised: "If sufficient tissue is available after the above testing has been completed, NGS may be considered."➤ New bullet was added: "If anemia is suspected, See NCCN Guidelines for Hematopoietic Growth Factors."Clinical Stage; Locoregional (cM0) pathway; Additional Evaluation: "Consider laparoscopy with cytology (category 2B)" was recommended for all patients in this pathway.This recommendation was changed as follows: ➤ Medically fit, potentially resectable: changed to "Recommend laparoscopy with cytology."➤ Medically fit, surgically unresectable: "consider laparoscopy with cytology" changed from category 2B to category 2A.
PLoS Medicine Issue Image | Vol. 7(11) November 2010
Journal: PLoS Medicine (2010)

Estimates of global health indicators—which give insight into death and disease rates, document advances in development, and help policymakers monitor progress—are absolutely essential for improving global health. Estimates, however, are always imperfect and are sometimes fiercely debated. Recently, new players from academia have entered the game of global health estimation, once the chief domain of United Nations agencies such as WHO. This has created some controversy but also an opportunity to reflect. In November 2010, PLoS Medicine published a cluster of six articles from a series of experts that provide insights and opinion on what estimates mean for global health and how to move forward with better data, measurement, coordination, and leadership. The cluster includes the perspectives of WHO, the Institute for Health Metrics and Evaluation (IHME), and stakeholders from low- and middle-income countries, as well as the PLoS Medicine Editors. Image Credit: D. Sharon Pruitt
Officials of the Association 1985-1986
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assisted Suicide and Euthanasia: A Comparative Analysis of Dutch and East Asian Cases
Authors: Yuming Wang, Hui Zhang, Zhenxiang Zhang, Yue Gu, Fengmin Shao
Journal: The American Journal of Bioethics (2022)

This article refers to:From Reciprocity to Autonomy in Physician-Assisted Death: An Ethical Analysis of the Dutch Supreme Court Ruling in the Albert Heringa Case
Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas
Authors: Jasmin Jo, Martin J van den Bent, Burt Nabors, Patrick Y Wen, David Schiff
Journal: Neuro-Oncology (2022)

Abstract With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. Other available guidelines have yet to incorporate the molecular biomarkers that inform the WHO classification of gliomas, and in some cases do not adequately consider current knowledge on IDHmt glioma growth rate and recurrence patterns. Moreover, these guidelines also do not provide specific recommendations for concerning clinical symptoms or radiographic findings warranting imaging studies out of prespecified intervals. Focusing on molecularly defined grade 2 and 3 IDHmt astrocytomas and oligodendrogliomas, we review current knowledge of tumor growth rates and time to tumor progression for each tumor type and propose a range of recommended MRI surveillance intervals for both the newly diagnosed and recurrent tumor setting. Additionally, we summarize situations in which imaging is advisable outside of these intervals.
Movable Kidney.
Authors: H. W. Lincoln
Journal: JAMA (1901)

Brooklyn, N. Y., Feb. 19. 1901. <h3>To the Editor:</h3> —I note with great pleasure, inThe Journalof February 9, the paper entitled "Movable Kidney from the Standpoint of the General Practitioner," by Dr. Alexander Marcy, Jr. As these cases are very often of a neurasthenic type, I should like to suggest the employment of lupulin and sumbul combined with either the tincture or extract of nucis vomicæ. There can be no question of the permanent benefit derived from massage and hydrotherapy, properly carried out. Coming now to the local, or mechanical management of nephroptosis, permit me to again call attention to the plaster bandage described by me in the<i>Medical News</i>of Sept. 1, 1900, mentioned also by Rose in the Post-Graduate for March, 1900. This device is the most satisfactory in every way, of any form of abdominal support, which has come to my notice. It is inexpensive,
Thrombin and Fibrinogen Play a Critical Role in Atopic Dermatitis Pathogenesis
Authors: Michael Sherenian, Alyssa Filuta, Peter Amezcua, Brandy Ruff, John Kroner, Brittany Grashel, Hua He, Chloe Hicks, Cassandra Almasri, Jocelyn Biagini, Lisa Martin, Joseph Palumbo, Gurjit Khurana Hershey
Journal: Journal of Allergy and Clinical Immunology (2022)
The Indian Health Service and American Indian/Alaska Native Health Outcomes
Authors: Gina Kruse, Victor A. Lopez-Carmen, Anpotowin Jensen, Lakotah Hardie, Thomas D. Sequist
Journal: Annual Review of Public Health (2022)

The Indian Health Service (IHS) has made huge strides in narrowing health disparities between American Indian and Alaska Native (AI/AN) populations and other racial and ethnic groups. Yet, health disparities experienced by AI/AN people persist, with deep historical roots combined with present-day challenges. Here we review the history of the IHS from colonization to the present-day system, highlight persistent disparities in AI/AN health and health care, and discuss six key present-day challenges: inadequate funding, limited human resources, challenges associated with transitioning services from federal to Tribal control through contracting and compacting, evolving federal and state programs, the need for culturally sensitive services, and the promise and challenges of health technology.
S101: COMBINATION OF A LUSPATERCEPT-LIKE DRUG (RAP-GRL) AND TMPRSS6-ASO IS SUPERIOR TO EITHER DRUG ALONE FOR CORRECTING β-THALASSEMIA
Authors: A. Guerra, P. Demsko, S. Sinha, P. McVeigh, C. Castruccio Castracani, L. Breda, C. Casu, S. Rivella
Journal: HemaSphere (2022)

The hallmarks of β-thalassemia (BT) include ineffective erythropoiesis (IE), splenomegaly and iron overload (IO). Recent studies have pointed to iron restriction (IR) to improve both anemia and IO in BT (Rivella, 2019). The decrease of iron-uptake by early erythroid cells results in reduced hemichrome toxicity and prevents premature red blood cell (RBC) hemolysis. One promising IR therapy strategy, which is currently in Phase II clinical trials (NCT04059406), targets the matriptase-2 (TMPRSS6) gene using antisense oligonucleotide technology (T-ASO). As previously shown, treatment of Hbbth3/+ (th3/+) mice (a mouse model for BT-intermedia) with T-ASO improves anemia, lengthens RBC lifespan, reduces levels of erythroferrone (ERFE), decrease hemichromes and lowers reactive oxygen species (ROS), and ameliorates splenomegaly (Casu et al., 2016, 2020; Guo et al., 2013). Another novel therapeutic approach to improve anemia in BT targets the TGF-β pathway. Luspatercept, a TGF-β ligand trap, gained FDA approval in 2019 to treat transfusion dependent BT patients (Cappellini and Taher, 2021). In mouse models of BT, its murine analog (RAP-536) was found to promote erythropoietin (EPO)-independent maturation of late-stage erythroid cells, resulting in increased RBC parameters in a dose-dependent manner (Suragani et al., 2014). In this work we generated a Luspatercept-like protein (RAP-GRL) and used it to treat th3/+ mice in combination with T-ASO (RAP-GRL+T-ASO). Our goal was to investigate if this strategy would successfully target distinct morbidities associated with BT. We generated RAP-GRL against the mouse analog of Luspatercept (RAP-536). Wild-type (WT) and th3/+ mice were subcutaneously injected s.c. with 10mg/kg of purified RAP-GRL. Our results showed that treatment with RAP-GRL increased RBC levels in both WT and th3/+ mice. Next, we treated th3/+ mice with RAP-GRL (10mg/kg), T-ASO (5mg/kg), or RAP-GRL+T-ASO. The RAP-GRL+T-ASO group displayed the most pronounced increase in RBC parameters and improvements in cell morphology. Flow cytometry analysis using CD71, TER119, and CD44 antibodies of the RAP-GRL+T-ASO groups showed the greatest improvements in IE in both the bone marrow (BM) and spleen (SPL). Additionally, splenomegaly was also greatly reduced in all T-ASO and RAP-GRL+T-ASO groups compared to RAP-GRL and control groups. In conclusion our results provide pre-clinical support for combining IR and TFG-β ligand-trap strategies for the treatment of BT. Our data provides evidence that IR, in conjunction with the erythroid maturation action of Luspatercept may offer additive and more effective therapeutic strategy for BT patients. References 1. Cappellini et al, Blood Adv 2021; 1:326–33 2. Casu et al, Blood 2021; 136:1968–79 3. Casu et al, Haematologica; 2016 101:e8-11 4. Guo et al, J Clin Invest 2013; 123:1531–41 5. Suragani et al, Nat Med 2014; 20:408–14
TCT-165 5-Year Clinical Results of a Randomized Trial Evaluating the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in De Novo Native Coronary Artery Lesions: Data From the ABSORB Japan Trial
Authors: Ken Kozuma, Takeshi Kimura, Kengo Tanabe
Journal: Journal of the American College of Cardiology (2019)